Abstract
Antiviral therapy for chronic hepatitis C has dramatically advanced since the discovery of the hepatitis C virus (HCV) in 1989 and the introduction of interferon (IFN) monotherapy in the early 1990s. The current standard therapy uses a combination of pegylated IFN and ribavirin. The duration of therapy and response to therapy are HCV genotype-specific. Genotype 1 patients require 48 weeks of the combination therapy for 50% successful viral elimination, while genotype 2 patients require 24 weeks of therapy for 80% or 90% viral elimination. Early viral kinetics after the initiation of therapy is a useful predictor of the sustained virologic response (SVR), which is formally determined at 24 weeks after completion of the treatment. For example, an early virologic response, which is determined by a 2-log reduction of HCV RNA or viral elimination at 12 weeks after the initiation of therapy, is a strong negative predictor of SVR in genotype 1 patients. In contrast, a rapid virologic response of HCV RNA-negative at 4 weeks after the initiation of therapy identifies genotype 2 “super-responders,” who may require a shorter period of therapy. Adherence to therapy is one of the most important factors for successful viral clearance. Hematopoietic growth factors such as epoetin and granulocyte-colony stimulating factor help reduce therapy-mediated cytopenia and improve patient compliance, thereby leading to better viral clearance. New types of anti-HCV agents such as HCV protease and polymerase inhibitors are needed for those patients that do not respond to combination therapy.
Similar content being viewed by others
References
QL Choo G Kuo AJ Weiner LR Overby DW Bradley M Houghton (1989) ArticleTitleIsolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 244 359–62 Occurrence Handle1:CAS:528:DyaL1MXit1Khtrk%3D Occurrence Handle2523562
InstitutionalAuthorNameAnonymous (1999) ArticleTitleGlobal surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium J Viral Hepat 6 35–47
JH Hoofnagle KD Mullen DB Jones V Rustgi A Di Bisceglie M Peters et al. (1986) ArticleTitleTreatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report N Engl J Med 315 1575–8 Occurrence Handle1:STN:280:BiiD28vptlU%3D Occurrence Handle3097544
GL Davis LA Balart ER Schiff K Lindsay HC Bodenheimer SuffixJr RP Perrillo et al. (1989) ArticleTitleTreatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial N Engl J Med 321 1501–6 Occurrence Handle1:STN:280:By%2BD2czptFI%3D Occurrence Handle2509916
AM Di Bisceglie P Martin C Kassianides M Lisker-Melman L Murray J Waggoner et al. (1989) ArticleTitleRecombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial N Engl J Med 321 1506–10 Occurrence Handle1:STN:280:By%2BD2czptFM%3D Occurrence Handle2509917
H Hagiwara N Hayashi E Mita K Ueda T Takehara A Kasahara et al. (1992) ArticleTitleDetection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-α Hepatology 15 37–41 Occurrence Handle1:STN:280:By2D1M%2FpslY%3D Occurrence Handle1370161
H Hagiwara N Hayashi E Mita T Takehara A Kasahara H Fusamoto et al. (1993) ArticleTitleQuantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy Gastroenterology 104 877–883 Occurrence Handle1:STN:280:ByyC2sfosVM%3D Occurrence Handle8382646
E Mita N Hayashi H Hagiwara K Ueda Y Kanazawa A Kasahara et al. (1994) ArticleTitlePredicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer Dig Dis Sci 39 977–982 Occurrence Handle10.1007/BF02087547 Occurrence Handle1:STN:280:ByuB38fptVQ%3D Occurrence Handle7909743
A Kasahara N Hayashi N Hiramatsu M Oshita H Hagiwara K Katayama et al. (1995) ArticleTitleAbility of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial Hepatology 21 291–7 Occurrence Handle10.1016/0270-9139(95)90083-7 Occurrence Handle1:STN:280:ByqC2cngt1M%3D Occurrence Handle7843696
P Marcellin N Boyer E Giostra C Degott AM Courouce F Degos et al. (1991) ArticleTitleRecombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France Hepatology 13 393–7 Occurrence Handle10.1016/0270-9139(91)90288-7 Occurrence Handle1:STN:280:By6C2Mzns1Y%3D Occurrence Handle1900254
X Causse H Godinot M Chevallier P Chossegros F Zoulim D Ouzan et al. (1991) ArticleTitleComparison of 1 or 3 MU of interferon alpha-2b and placebo in patients with chronic non-A, non-B hepatitis Gastroenterology 101 497–502 Occurrence Handle1:STN:280:By6B1MzltFA%3D Occurrence Handle1906028
KL Lindsay GL Davis ER Schiff HC Bodenheimer LA Balart JL Dienstag et al. (1996) ArticleTitleResponse to higher dose of interferon alpha-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group Hepatology 24 1034–40 Occurrence Handle1:STN:280:ByiD28%2FjtlI%3D Occurrence Handle8903371
T Poynard V Leroy M Cohard T Thevenot P Mathurin P Opolon et al. (1996) ArticleTitleMeta-analysis of interferon randomized trials in the treatment of viral hepatitis: effect of dose and duration Hepatology 24 778–89 Occurrence Handle1:CAS:528:DyaK28XmvFOisb4%3D Occurrence Handle8855176
NC Tassopoulos G Karvountzis G Touloumi JK Delladetsima GV Papatheodoridis A Katsoulidou et al. (1996) ArticleTitleComparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: a randomized controlled trial Am J Gastroenterol 91 1734–8 Occurrence Handle1:CAS:528:DyaK28XlvVGqsLc%3D Occurrence Handle8792690
T Poynard P Marcellin SS Lee C Niederau GS Minuk G Ideo et al. (1998) ArticleTitleRandomized trial of interferon alpha-2b and ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus Lancet 352 1426–32 Occurrence Handle10.1016/S0140-6736(98)07124-4 Occurrence Handle1:CAS:528:DyaK1cXnsVSmsLg%3D Occurrence Handle9807989
JG McHutchison SC Gordon ER Schiff ML Shiffman WM Lee VK Rustgi et al. (1998) ArticleTitleInterferon alpha-2b and ribavirin as initial treatment of relapse of chronic hepatitis C N Engl J Med 339 1485–92 Occurrence Handle10.1056/NEJM199811193392101 Occurrence Handle1:CAS:528:DyaK1cXnslGmtbs%3D Occurrence Handle9819446
N Hiramatsu A Kasahara F Nakanishi T Toyama M Tsujii S Tsuji et al. (2004) ArticleTitleThe significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan Hepatol Res 29 142–7 Occurrence Handle1:CAS:528:DC%2BD2cXltVGgsrc%3D Occurrence Handle15203077
M Rumi E Del Ninno ML Parravicini R Romeo R Soffredini MF Donato et al. (1996) ArticleTitleA prospective randomized trial comparing lymphoblastoid to recombinant interferon alpha 2a as therapy for chronic hepatitis C Hepatology 24 1366–70 Occurrence Handle1:CAS:528:DyaK2sXpt1Cmtg%3D%3D Occurrence Handle8938163
MJ Tong KR Reddy WM Lee PJ Pockros JC Hoefs EB Keeffe et al. (1997) ArticleTitleTreatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Group Hepatology 26 747–54 Occurrence Handle1:CAS:528:DyaK2sXmt1CktrY%3D Occurrence Handle9303508
AU Neumann NP Lam H Dahari DR Gretch TE Wiley TJ Layden et al. (1998) ArticleTitleHepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy Science 282 103–7 Occurrence Handle10.1126/science.282.5386.103 Occurrence Handle1:CAS:528:DyaK1cXmsFOjsLc%3D Occurrence Handle9756471
S Zeuzem JM Schmidt JH Lee B Ruster WK Roth (1996) ArticleTitleEffect of interferon alpha on the dynamics of hepatitis C virus turnover in vivo Hepatology 23 366–71 Occurrence Handle1:STN:280:BymC283gs1A%3D Occurrence Handle8591865
KA Nieforth R Nadeau IH Patel D Mould (1996) ArticleTitleUse of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alpha-2a and a polyethylene glycol-modified derivative in healthy subjects Clin Pharmacol Ther 59 636–46 Occurrence Handle10.1016/S0009-9236(96)90003-X Occurrence Handle1:CAS:528:DyaK28XksFemurY%3D Occurrence Handle8681488
S Zeuzem SV Feinman J Rasenack EJ Heathcote MY Lai E Gane et al. (2000) ArticleTitlePeginterferon alpha-2a in patients with chronic hepatitis C N Engl J Med 343 1666–72 Occurrence Handle10.1056/NEJM200012073432301 Occurrence Handle1:CAS:528:DC%2BD3cXovVGhurY%3D Occurrence Handle11106715
EJ Heathcote ML Shiffman WG Cooksley GM Dusheiko SS Lee L Balart et al. (2000) ArticleTitlePeginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis N Engl J Med 343 1673–80 Occurrence Handle10.1056/NEJM200012073432302 Occurrence Handle1:CAS:528:DC%2BD3cXovVGhurc%3D Occurrence Handle11106716
KL Lindsay C Trepo T Heintges ML Shiffman SC Gordon JC Hoefs InstitutionalAuthorNameHepatitis Interventional Therapy Group K Lindsay et al. (2001) ArticleTitleA randomized, double-blind trial comparing PEGylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatitis C. Hepatology 34 395–403 Occurrence Handle1:CAS:528:DC%2BD3MXmtVGqtLs%3D
MP Manns JG McHutchison SC Gordon VK Rustgi M Shiffman R Reindoller et al. (2001) ArticleTitlePeginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial Lancet 358 958–65 Occurrence Handle10.1016/S0140-6736(01)06102-5 Occurrence Handle1:CAS:528:DC%2BD3MXntF2qtb8%3D Occurrence Handle11583749
MW Fried ML Shiffman KR Reddy C Smith G Marinos FL Goncales SuffixJr et al. (2002) ArticleTitlePeginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 975–82 Occurrence Handle10.1056/NEJMoa020047 Occurrence Handle1:CAS:528:DC%2BD38Xnt12rtb0%3D Occurrence Handle12324553
G Dusheiko (1997) ArticleTitleSide effects of alpha interferon in chronic hepatitis C Hepatology 26 112S–21S Occurrence Handle10.1002/hep.510260720 Occurrence Handle1:CAS:528:DyaK2sXmt1CktL8%3D Occurrence Handle9305675
HC Bodenheimer SuffixJr KL Lindsay GL Davis JH Lewis SN Thung LB Seeff (1997) ArticleTitleTolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial Hepatology 26 473–7 Occurrence Handle10.1002/hep.510260231 Occurrence Handle1:CAS:528:DyaK2sXlsVWjur4%3D Occurrence Handle9252161
GL Davis R Esteban-Mur V Rustgi J Hoefs SC Gordon C Trepo et al. (1998) ArticleTitleInterferon alpha-2b alone or in combination with ribavirin for the treatment or relapse of chronic hepatitis C N Engl J Med 339 1493–9 Occurrence Handle10.1056/NEJM199811193392102 Occurrence Handle1:CAS:528:DyaK1cXnslGmtbg%3D Occurrence Handle9819447
O Reichard G Norkrans A Fryden JH Braconier A Sonnerborg O Weiland (1998) ArticleTitleRandomized double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C Lancet 351 83–6 Occurrence Handle10.1016/S0140-6736(97)06088-1 Occurrence Handle1:CAS:528:DyaK1cXmsFSqtw%3D%3D Occurrence Handle9439491
SJ Hadziyannis H Sette SuffixJr TR Morgan V Balan M Diago P Marcellin et al. (2004) ArticleTitlePeginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 346–55 Occurrence Handle1:CAS:528:DC%2BD2cXitlOktrg%3D Occurrence Handle14996676
S Iino K Okita M Omata H Kumada N Hayashi K Tanikawa (2004) ArticleTitleClinical efficacy of PEG-Interferon α-2b and ribavirin combination therapy for 48 weeks in chronic hepatitis C patients with genotype 1 and high viral load—retrospective comparison with Interferon α-2b and ribavirin combination therapy for 24 weeks KanTanSui 49 1099–121
AM Di Bisceglie JH Hoofnagle (2002) ArticleTitleOptimal therapy of hepatitis C Hepatology 36 S121–7 Occurrence Handle10.1002/hep.1840360716 Occurrence Handle12407585
GL Davis JB Wong JG McHutchison MP Manns J Harvey J Albrecht (2003) ArticleTitleEarly virologic response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C Hepatology 38 645–52 Occurrence Handle1:CAS:528:DC%2BD3sXnvVKjt7s%3D Occurrence Handle12939591
DB Strader T Wright DL Thomas LB Seeff (2004) ArticleTitleAmerican Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C Hepatology 39 1147–71 Occurrence Handle10.1002/hep.20119 Occurrence Handle15057920
GL Drusano SL Preston (2004) ArticleTitleA 48-week duration of therapy with pegylated interferon α2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus J Infect Dis 189 964–70 Occurrence Handle1:CAS:528:DC%2BD2cXjtF2mtrc%3D Occurrence Handle14999598
M Buti A Valdes F Sanchez-Avila R Esteban (2003) ArticleTitleExtending combination therapy with peginterferon alpha-2a plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases Hepatology 37 1226–7 Occurrence Handle10.1053/jhep.2003.50107 Occurrence Handle12717407
P Ferenci U Bergholz H Laferl C Gurguta A Maieron M Gschwantler et al. (2005) ArticleTitleIs shorter treatment with peginterferon alpha-2a (40 KD) plus ribavirin possible in HCV genotype 1 “super-responder”? preliminary results of a prospective randomized clinical trial Hepatology 42 218A
A Mangia R Santoro N Minerva GL Ricci V Carretta M Persico et al. (2005) ArticleTitlePeginterferon alpha-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3 N Engl J Med 352 2609–17 Occurrence Handle10.1056/NEJMoa042608 Occurrence Handle1:CAS:528:DC%2BD2MXls1ajsro%3D Occurrence Handle15972867
M Wagner M Huber T Berg H Hinrichsen J Rasenack T Heintges et al. (2005) ArticleTitlePeginterferon-α-2a (40 KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C Gastroenterology 129 522–7
JG McHutchison M Manns K Patel T Poynard KL Lindsay C Trepo et al. (2002) ArticleTitleAdherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C Gastroenterology 123 1061–9 Occurrence Handle10.1053/gast.2002.35950 Occurrence Handle1:CAS:528:DC%2BD38Xotl2gurk%3D Occurrence Handle12360468
NH Afdhal DT Dieterich PJ Pockros ER Schiff ML Shiffman MS Sulkowski et al. (2004) ArticleTitleEpoetin alpha maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study Gastroenterology 126 1302–11 Occurrence Handle10.1053/j.gastro.2004.01.027 Occurrence Handle1:CAS:528:DC%2BD2cXksF2qtLg%3D Occurrence Handle15131791
PJ Pockros ML Shiffman ER Schiff MS Sulkowski Z Younossi DT Dieterich et al. (2004) ArticleTitleEpoetin alpha improves quality of life in anemic HCV-infected patients receiving combination therapy Hepatology 40 1450–8 Occurrence Handle10.1002/hep.20482 Occurrence Handle1:CAS:528:DC%2BD2MXhslaguw%3D%3D Occurrence Handle15565613
P Marcellin S Levy S Erlinger (1997) ArticleTitleTherapy of hepatitis C: patients with normal aminotransferase levels Hepatology 26 133S–6S Occurrence Handle10.1002/hep.510260723 Occurrence Handle1:CAS:528:DyaK2sXmt1CktLo%3D Occurrence Handle9305678
InstitutionalAuthorNameAnonymous (1999) ArticleTitleEASL international consensus conference on hepatitis C. Consensus statement J Hepatol 30 956–62
L Serfaty O Chazouilleres JM Pawlotsky T Andreani C Pellet R Poupon (1996) ArticleTitleInterferon alpha therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity Gastroenterology 110 291–5 Occurrence Handle10.1053/gast.1996.v110.pm8536870 Occurrence Handle1:CAS:528:DyaK28XhtFKitbc%3D Occurrence Handle8536870
A Sangiovanni R Morales G Spinzi M Rumi A Casiraghi R Ceriani et al. (1998) ArticleTitleInterferon alpha treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study Hepatology 27 853–6 Occurrence Handle10.1002/hep.510270330 Occurrence Handle1:CAS:528:DyaK1cXhslGhs7k%3D Occurrence Handle9500717
A Rossini A Ravaggi L Biasi E Agostinelli L Bercich GB Gazzola et al. (1997) ArticleTitleVirological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis Hepatology 26 1012–7 Occurrence Handle1:STN:280:ByiH28npvVw%3D Occurrence Handle9328328
AM Di Bisceglie J Thompson N Smith-Wilkaitis EM Brunt BR Bacon (2001) ArticleTitleCombination of interferon and ribavirin in chronic hepatitis C: re-treatment of non-responders to interferon Hepatology 33 704–7 Occurrence Handle10.1053/jhep.2001.22346 Occurrence Handle1:CAS:528:DC%2BD3MXit1emtLg%3D Occurrence Handle11230751
CK Hui A Monto T Belaye E Lau TL Wright (2003) ArticleTitleOutcomes of interferon α and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransferases Gut 52 1644–8 Occurrence Handle10.1136/gut.52.11.1644 Occurrence Handle1:CAS:528:DC%2BD3sXpsFyks70%3D Occurrence Handle14570736
S Zeuzem M Diago E Gane KR Reddy P Pockros D Prati et al. (2004) ArticleTitlePeginterferon alpha-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels Gastroenterology 127 1724–32 Occurrence Handle10.1053/j.gastro.2004.09.050 Occurrence Handle1:CAS:528:DC%2BD2MXit1Gjtg%3D%3D Occurrence Handle15578510
S Zeuzem C Sarrazin R Rouzier A Tarral N Brion N Forestier et al. (2005) ArticleTitleAnti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 patients refractory to pegylated interferon (PEG-IFN-α) Hepatology 42 IssueIDSuppl 1 233A
S Zeuzem C Sarrazin F Wagner R Rouzier N Forester S Gupta et al. (2005) ArticleTitleCombination therapy with the HCV protease inhibitor, SCH 503034, plus Peg-Intron in hepatitis C genotype-1 Peg-Intron non-responder Hepatology 42 IssueIDSuppl 1 233A
HW Reesink S Zeuzem CJ Weegink N Forester A van Vliet LA McNair et al. (2005) ArticleTitleFinal results of a phase 1b, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor Hepatology 42 IssueIDSuppl 1 234A
E Foy K Li C Wang R Sumpter SuffixJr M Ikeda SM Lemon et al. (2003) ArticleTitleRegulation of interferon regulatory factor-3 by the hepatitis C virus serine protease Science 300 1145–8 Occurrence Handle10.1126/science.1082604 Occurrence Handle1:CAS:528:DC%2BD3sXjslGqtro%3D Occurrence Handle12702807
E Foy K Li R Sumpter SuffixJr YM Loo CL Johnson C Wang et al. (2005) ArticleTitleControl of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling Proc Natl Acad Sci U S A 102 2986–91 Occurrence Handle10.1073/pnas.0408707102 Occurrence Handle1:CAS:528:DC%2BD2MXitVSkt7s%3D Occurrence Handle15710892
C O'Brien E Godofsky M Rodriguez-Torres N Afdhal SC Pappas P Pockros et al. (2005) ArticleTitleRandomized trial of valopicitabine (NM283), alone or with peginterferon, vs. retreatment with peginterferon plus ribavirin (PEGIFN/RBV) in hepatitis C patients with previous non-response to PEGIFN/RBV: first interim results Hepatology 42 IssueIDSuppl 1 234A
T Takehara N Hayashi (2005) ArticleTitleNatural killer cells in hepatitis C virus infection: from innate immunity to adaptive immunity Clin Gastroenterol Hepatol 3 S78–81 Occurrence Handle10.1016/S1542-3565(05)00702-0 Occurrence Handle1:CAS:528:DC%2BD2MXhtF2ms7zP Occurrence Handle16234066
BR Bacon JG McHutchison SC Gordon NH Afdhal IM Jacobson M Shiffman et al. (2005) ArticleTitleSafety, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of CPG 10101 (Actilon), a novel TLR9 agonist: comparison of normal volunteers and HCV infected individuals Gastroenterology 128 IssueIDSuppl 2 P-91
B Kerr L Bauman S Webber A Xiang J Ng L Kirkovsky et al. (2005) ArticleTitlePharmacokinetics, safety, and tolerability of the isatorbine oral prodrug ANA975 in a phase 1 healthy volunteer study Hepatology 42 IssueIDSuppl 1 533A
JJ Feld JH Hoofnagle (2005) ArticleTitleMechanisms of action of interferon and ribavirin in treatment of hepatitis C Nature 436 967–72 Occurrence Handle10.1038/nature04082 Occurrence Handle1:CAS:528:DC%2BD2MXotFent7c%3D Occurrence Handle16107837
K Lindahl L Stahle A Bruchfeld R Schvarcz (2005) ArticleTitleHigh-dose ribavirin in combination with standard dose PEGinterferon for treatment of patients with chronic hepatitis C Hepatology 41 275–9 Occurrence Handle10.1002/hep.20563 Occurrence Handle1:CAS:528:DC%2BD2MXhsVansbg%3D Occurrence Handle15660393
RG Gish D Nelson S Arora MW Fried KR Reddy Y Xu et al. (2005) ArticleTitleVirologic response and safety outcomes in therapy-naïve patients treated for chronic hepatitis C with viramidine in combination with pegylated interferon alpha-2a Gastroenterology 128 IssueIDSuppl 2 P-11
A Kasahara N Hayashi K Mochizuki M Takayanagi K Yoshioka S Kakumu et al. (1998) ArticleTitleRisk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group Hepatology 27 1394–402 Occurrence Handle10.1002/hep.510270529 Occurrence Handle1:CAS:528:DyaK1cXjtVSjt7Y%3D Occurrence Handle9581697
A Kasahara H Tanaka T Okanoue Y Imai H Tsubouchi K Yoshioka et al. (2004) ArticleTitleInterferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death J Viral Hepat 11 148–56 Occurrence Handle10.1046/j.1365-2893.2003.00481.x Occurrence Handle1:STN:280:DC%2BD2c7jvFShtA%3D%3D Occurrence Handle14996350
H Yoshida Y Shiratori M Moriyama Y Arakawa T Ide M Sata et al. (1999) ArticleTitleInterferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy Ann Intern Med 131 174–81 Occurrence Handle1:CAS:528:DyaK1MXlsVCrtbo%3D Occurrence Handle10428733
T Okanoue Y Itoh M Minami S Sakamoto K Yasui M Sakamoto et al. (1999) ArticleTitleInterferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group J Hepatol 30 653–9 Occurrence Handle10.1016/S0168-8278(99)80196-2 Occurrence Handle1:CAS:528:DyaK1MXjtVWqsbo%3D Occurrence Handle10207807
Y Imai S Kawata S Tamura I Yabuuchi S Noda M Inada et al. (1998) ArticleTitleRelation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group Ann Intern Med 129 94–9 Occurrence Handle1:CAS:528:DyaK1cXlt1emsbk%3D Occurrence Handle9669992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hayashi, N., Takehara, T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol 41, 17–27 (2006). https://doi.org/10.1007/s00535-005-1740-7
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s00535-005-1740-7